




PHARMACEUTICAL 2021

NEKTAR THERAPEUTICS Rank 158 of 402





PHARMACEUTICAL 2021

NEKTAR THERAPEUTICS Rank 158 of 402



The relative strengths and weaknesses of NEKTAR THERAPEUTICS are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NEKTAR THERAPEUTICS compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 40% points. The greatest weakness of NEKTAR THERAPEUTICS is the variable Other Liabilities, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 93% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	1,138,005
Cost of Goods Sold	19,477
Intangible Assets	76,501
Liabilities, Current	115,779
Liabilities, Non-Current	145,353
Other Assets	264,599
Other Compr. Net Income	-1,290
Other Expenses	45,682
Other Liabilities	200,340
Other Net Income	-18,836
Other Revenues	152,915
Property and Equipment	59,662
Research and Development	408,678
Selling, General and Administrative Expense	104,682

Output Variable	Value in 1000 USD
Assets	1,538,767
Liabilities	461,472
Expenses	578,519
Revenues	152,915
Stockholders Equity	1,077,295
Net Income	-444,440
Comprehensive Net Income	-445,085
Economic Capital Ratio	141%